Therapeutic Angiogenesis for Vascular Diseases

Molecular Mechanisms and Targeted Clinical Approaches for the Treatment of Angiogenic Disease

  • Mark Slevin

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Bin Zhang, Jian-xing Ma
    Pages 27-65
  3. Jacob M. Jones, Trevor McFarland, J. Timothy Stout
    Pages 67-80
  4. Jessica J. Kandel, Darrell J. Yamashiro, Jan Kitajewski
    Pages 81-93
  5. Frank D. Kolodgie, Aloke V. Finn, Jagat Narula, Renu Virmani
    Pages 213-236
  6. K-Raman Purushothaman, Meerarani Purushothaman, Andrew P. Levy, Samin K. Sharma, Valentin Fuster, Pedro R. Moreno
    Pages 237-256
  7. Konstantinos Toutouzas, Andreas Synetos, Christodoulos Stefanadis
    Pages 257-265
  8. John F. O’Sullivan, Anne-Laure Leblond, Noel M. Caplice
    Pages 267-294
  9. Adrià Arboix, Marta Grau-Olivares, Jerzy Krupinski
    Pages 313-338
  10. Philip C. Bennett, Stanley Silverman, Paramjit Gill, Gregory Y.H. Lip
    Pages 339-359
  11. Sarah L. Mackie, Ann W. Morgan, Pamela F. Jones
    Pages 383-402
  12. Ahmed Itrat, Ayeesha Kamal
    Pages 403-416
  13. Judith Sendra Cuadal, Mercè Morral, Marc Ramis-Castelltort
    Pages 417-424
  14. Back Matter
    Pages 425-430

About this book


Angiogenesis is the growth of new blood vessels and is a key process which occurs during pathological disease progression. Excessive and damaging angiogenesis occurs in diseases such as cancer, diabetic retinopathies, age-related macular degeneration and atherosclerosis. In other diseases such as stroke and myocardial infarction, insufficient or improper angiogenesis results in tissue loss and ultimately higher morbidity and mortality. In this book we will begin by providing the reader with an overview of the process of angiogenesis including normal embryological development of blood vessels. The following chapters will each focus on a key angiogenic disease incorporating current scientific knowledge concerning the causes of activation of the “angiogenic switch”, pathological consequences, current treatment options and future perspectives. Where appropriate, results from pre-clinical trials, novel imaging modalities and nanotechnological approaches will be incorporated into these sections. Finally, since it is now believed that the process of angiogenesis operated via different signalling mechanisms in different vascular beds, we will discuss our current understanding of this phenomenon. The target audience for this book would include researchers in all the basic sciences; post-graduate students at Universities and Institutes; pharmaceutical industries; clinicians working in vascular biology or tissue imaging; pathologists; neurologists; tumour biologists; ophthalmologists and cardiologists.


Angiogenesis Imaging Therapy

Editors and affiliations

  • Mark Slevin
    • 1
  1. 1., SBCHS, John Dalton BuildingManchester Metropolitan UniversityManchesterUnited Kingdom

Bibliographic information